Great Point Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Great Point Partners’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.6M	Sell	700,000 -1,050,000	-60%	-$16.2M	2.38%	18
2026 Q1	$24.3M	Hold	1,750,000	–	–	5.59%	4
2025 Q4	$21.1M	Buy	1,750,000 +50,000	+3%	+$679K	6.85%	2
2025 Q3	$23.1M	Sell	1,700,000 -300,000	-15%	-$2.82M	9.53%	1
2025 Q2	$12.8M	Buy	2,000,000 +188,004	+10%	+$914K	8.34%	3
2025 Q1	$6.41M	Buy	+1,811,996	New	+$6.45M	3.4%	12
2023 Q3	–	Sell	-968,795	Closed	-$20.9M	–	44
2023 Q2	$20.9M	Buy	968,795 +185,000	+24%	+$5M	4.09%	8
2023 Q1	$23M	Buy	783,795 +593,795	+313%	+$20.6M	4.52%	8
2022 Q4	$7.02M	Buy	+190,000	New	+$6.74M	1.38%	26

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Great Point Partners's AMLX Position: Q2 2026 in Review

Great Point Partners reduced its Amylyx Pharmaceuticals (AMLX) stake by 60% in Q2 2026, selling an estimated $16.2M and leaving 700,000 shares worth $12.6M. The position accounts for 2.38% of the portfolio, ranked #18.

Great Point Partners first reported a position in AMLX in Q4 2022 and has held it in 9 quarters since. The position peaked at $24.3M in Q1 2026. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Great Point Partners held 700,000 shares of Amylyx Pharmaceuticals worth $12.6M as of Q2 2026.
Great Point Partners sold 1,050,000 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $16.2M.
Amylyx Pharmaceuticals made up 2.38% of Great Point Partners's portfolio in Q2 2026, its #18 holding.
Great Point Partners first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 9 quarters since.
Great Point Partners's Amylyx Pharmaceuticals position peaked at $24.3M in Q1 2026.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.